News Theranos reaches tentative settlement with Walgreens Agreement could cost Theranos $30 million - significantly less than original $140 million lawsuit.
News Walgreens hits Theranos with $140m damages suit Walgreens claims to have been continually misled over Theranos' technology.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.